Last update Feb. 5, 2022
Very High Risk
Non-steroidal derivative of triphenylethylene that binds to estrogen receptors and has potent anti-estrogenic properties, similar to those of tamoxifen. It is used as antineoplastic hormonal therapy in the treatment of hormone-dependent metastatic breast cancer in post-menopausal patients. Oral administration.
At the date of the last update, there was no published data available on its excretion in human milk.
Although its pharmacokinetic data (large volume of distribution, moderately high molecular weight and very high percentage of protein binding) make it unlikely for it to pass into the mothers’ milk in a clinically significant quantity, its long elimination half-life (EMA 2006) could favor it.
Breastfeeding is practically impossible, since before breastfeeding again after the last administration of toremifene, it would be necessary to wait 5 half-lives (25 days) for 97% of it to be eliminated from the body. Meanwhile, the milk would have to be expressed and discarded regularly to maintain production.
We do not have alternatives for Toremifene Citrate.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM